RT Journal Article
SR Electronic
T1 SARS-CoV-2 seroprevalence in pregnant women during the first three COVID-19 waves in The Gambia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.06.09.23291201
DO 10.1101/2023.06.09.23291201
A1 Janha, Ramatoulie E.
A1 Bah, Alasana
A1 Jah, Hawanatu
A1 Touray, Fatima
A1 Idris, Yahaya
A1 Keita, Saikou
A1 Gaye, Yassin
A1 Jallow, Samba
A1 Faye-Joof, Tisbeh
A1 Njie, Baboucarr
A1 Craik, Rachel
A1 Mohammed, Nuredin I.
A1 von Dadelszen, Peter
A1 D’Alessandro, Umberto
A1 Roca, Anna
A1 the PRECISE Network
YR 2023
UL http://medrxiv.org/content/early/2023/06/12/2023.06.09.23291201.abstract
AB Objectives SARS-CoV-2 transmission in Sub-Saharan Africa has probably been underestimated. Population-based seroprevalence studies are needed to determine the extent of transmission in the continent.Methods Blood samples from a cohort of Gambian pregnant women were tested for SARS-CoV-2 total IgM/IgG before (Pre-pandemic1: October-December 2019 and Pre-pandemic2: February-June 2020) and during the pandemic (Post-wave1: October-December 2020, Post-wave2: May-June 2021; and Post-wave3: October-December 2021). Samples positive for total SARS-CoV-2 IgM/IgG were tested for protein-specific antibodies.Results SARS-CoV-2 total IgM/IgG seroprevalence was 0.9% 95%CI (0.2, 4.9) in Pre-pandemic1; 4.1% (1.4, 11.4) in Pre-pandemic2; 31.1% (25.2, 37.7) in Post-wave1; 62.5% (55.8, 68.8) in Post-wave2 and 90.0% (85.1, 93.5) in Post-wave3. S-protein IgG and NCP-protein IgG seroprevalence also increased at each Post-wave period. Although S-protein IgG and NCP-protein IgG seroprevalence was similar at Post-wave1, S-protein IgG seroprevalence was higher at Post-wave2 and Post-wave3, [prevalence difference (PD) 13.5 (0.1, 26.8) and prevalence ratio (PR) 1.5 (1.0, 2.3) in Post-wave2; and 22.9 (9.2, 36.6) and 1.4 (1.1, 1.8) in Post-wave3 respectively, p<0.001].Conclusion SARS-CoV-2 transmission in The Gambia during the first three COVID-19 waves was high, differing significantly from official numbers of COVID-19 cases reported. Our findings are important for policy makers in managing the near-endemic COVID-19.HighlightsHigh specificity of the IgM/IgG SARS-CoV-2 test using samples collected prepandemicVery high (>90%) SARS-CoV-2 seroprevalence after third COVID-19 wave in The GambiaHigh SARS-CoV-2 transmission contrasts with low number of COVID-19 reported casesCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by Medical Research Council UK Research and Innovation [grant numbers MR/P027938/1, MC_PC_20028 and MC_PC_19084]. The funders had no role in the study design; collection, analysis and interpretation of data; or writing of the manuscript and decision to publish.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Joint Ethics committee/IRB of The Gambia Government/MRCG at LSHTM and the London School of Hygiene and Tropical Medicine Observational Ethics Committee gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.